A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Trial Profile

A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SOAR
  • Sponsors Rigel Pharmaceuticals
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Apr 2019.
    • 05 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Apr 2019.
    • 03 Oct 2017 Preliminary results of stage 1 are presented in the Rigel media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top